Tumor Cell Plasticity in Cancer: Signaling Pathways and Pharmaceutical Interventions

Abstract

Cellular plasticity, the ability of cells to dynamically alter their phenotypes, is a key driver of tumor evolution. This process is a hallmark of cancer which enables the acquisition of malignant traits, leading to metastasis, progression, and therapy resistance. It is governed by cell-intrinsic factors, such as genomic instability and epigenetic reprogramming, and extrinsic stimuli from the tumor microenvironment. However, a unified framework is still needed to position plasticity as the central process that links these drivers to diverse cancer hallmarks. In this review, we first explore how plasticity enables key steps of tumor evolution, including tumorigenesis, metastasis driven by epithelial–mesenchymal plasticity (EMP), therapy resistance, and cancer stem cell (CSC) dynamics. We then summarize the intrinsic and extrinsic mechanisms that govern this adaptability. Finally, we discuss clinical advances in monitoring and targeting plasticity and highlight how new spatiotemporal technologies can address current research challenges. This review provides a framework positioning cellular plasticity as a central mechanism in cancer evolution, connecting its fundamental drivers to clinical translation. By synthesizing the latest advances, we offer perspectives for developing therapies that integrate prediction, monitoring, and targeting of plasticity to proactively guide cancer evolution toward manageable outcomes.

Keywords

differentiation therapy / epigenetic reprogramming / spatiotemporal omics / therapy resistance / tumor cell plasticity / tumor evolution / tumor microenvironment

References

[1] A. Pérez-González, K. Bévant, and C. Blanpain, “Cancer Cell Plasticity During Tumor Progression, Metastasis and Response to Therapy,” Nature Cancer 4 (2023): 1063–1082.

[2] A. J. Merrell and B. Z. Stanger, “Adult Cell Plasticity In Vivo: De-Differentiation and Transdifferentiation Are Back in Style,” Nature Reviews Molecular Cell Biology 17 (2016): 413–425.

[3] S. Yuan, R. J. Norgard, and B. Z. Stanger, “Cellular Plasticity in Cancer,” Cancer Discovery 9 (2019): 837–851.

[4] R. L. Davis, H. Weintraub, and A. B. Lassar, “Expression of a Single Transfected cDNA Converts Fibroblasts to Myoblasts,” Cell 51 (1987): 987–1000.

[5] K. Takahashi and S. Yamanaka, “Induction of Pluripotent Stem Cells From Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors,” Cell 126 (2006): 663–676.

[6] J. Beumer and H. Clevers, “Hallmarks of Stemness in Mammalian Tissues,” Cell Stem Cell 31 (2024): 7–24.

[7] K. R. Jessen, R. Mirsky, and P. Arthur-Farraj, “The Role of Cell Plasticity in Tissue Repair: Adaptive Cellular Reprogramming,” Developmental Cell 34 (2015): 613–620.

[8] D. Hanahan, “Hallmarks of Cancer: New Dimensions,” Cancer Discovery 12 (2022): 31–46.

[9] A. Mehta and B. Z. Stanger, “Lineage Plasticity: The New Cancer Hallmark on the Block,” Cancer Research 84 (2024): 184–191.

[10] S. Raghavan, P. S. Winter, A. W. Navia, et al., “Microenvironment Drives Cell State, Plasticity, and Drug Response in Pancreatic Cancer,” Cell 184 (2021): 6119–6137. e6126.

[11] J. Haerinck, S. Goossens, and G. Berx, “The Epithelial-Mesenchymal Plasticity Landscape: Principles of Design and Mechanisms of Regulation,” Nature Reviews Genetics 24 (2023): 590–609.

[12] A. P. Feinberg and A. Levchenko, “Epigenetics as a Mediator of Plasticity in Cancer,” Science (New York, NY) 379 (2023): eaaw3835.

[13] P. B. Gupta, I. Pastushenko, A. Skibinski, C. Blanpain, and C. Kuperwasser, “Phenotypic Plasticity: Driver of Cancer Initiation, Progression, and Therapy Resistance,” Cell Stem Cell 24 (2019): 65–78.

[14] A. Davies, A. Zoubeidi, H. Beltran, and L. A. Selth, “The Transcriptional and Epigenetic Landscape of Cancer Cell Lineage Plasticity,” Cancer Discovery 13 (2023): 1771–1788.

[15] A. M. Krebs, J. Mitschke, M. Lasierra Losada, et al., “The EMT-Activator Zeb1 Is a Key Factor for Cell Plasticity and Promotes Metastasis in Pancreatic Cancer,” Nature Cell Biology 19 (2017): 518–529.

[16] L. Lan, T. Evan, H. Li, et al., “GREM1 Is Required to Maintain Cellular Heterogeneity in Pancreatic Cancer,” Nature 607 (2022): 163–168.

[17] P. Mu, Z. Zhang, M. Benelli, et al., “SOX2 Promotes Lineage Plasticity and Antiandrogen Resistance in TP53- and RB1-Deficient Prostate Cancer,” Science (New York, NY) 355 (2017): 84–88.

[18] M. A. Taylor, E. Kandyba, K. Halliwill, et al., “Stem-Cell States Converge in Multistage Cutaneous Squamous Cell Carcinoma Development,” Science (New York, NY) 384 (2024): eadi7453.

[19] X. Tong, A. S. Patel, E. Kim, et al., “Adeno-to-Squamous Transition Drives Resistance to KRAS Inhibition in LKB1 Mutant Lung Cancer,” Cancer Cell 42, no. 3 (2024): 413–428.e7, https://doi.org/10.1016/j.ccell.2024.01.012.

[20] C. Burdziak, D. Alonso-Curbelo, T. Walle, et al., “Epigenetic Plasticity Cooperates With Cell-Cell Interactions to Direct Pancreatic Tumorigenesis,” Science (New York, NY) 380 (2023): eadd5327.

[21] N. D. Marjanovic, M. Hofree, J. E. Chan, et al., “Emergence of a High-Plasticity Cell State During Lung Cancer Evolution,” Cancer Cell 38 (2020): 229–246. e213.

[22] C. Chen, W. Tran, K. Song, et al., “Temporal Evolution Reveals Bifurcated Lineages in Aggressive Neuroendocrine Small Cell Prostate Cancer Trans-Differentiation,” Cancer Cell 41, no. 12 (2023): 2066–2082.e9, https://doi.org/10.1016/j.ccell.2023.10.009.

[23] K. P. Simeonov, C. N. Byrns, M. L. Clark, et al., “Single-Cell Lineage Tracing of Metastatic Cancer Reveals Selection of Hybrid EMT States,” Cancer Cell 39 (2021): 1150–1162. e1159.

[24] A. W. Lambert, Y. Zhang, and R. A. Weinberg, “Cell-Intrinsic and Microenvironmental Determinants of Metastatic Colonization,” Nature Cell Biology 26 (2024): 687–697.

[25] I. Vathiotis, A. Banerjee, U. Sen, et al., “Histologic Transformation in Cancer: The Path for Clinical Translation,” Cancer Discovery 15 (2025): 1783–1793.

[26] E. W. Thompson, A. D. Redfern, S. Brabletz, et al., “EMT and Cancer: What Clinicians Should Know,” Nature Reviews Clinical Oncology 22, no. 10 (2025): 711–733, https://doi.org/10.1038/s41571-025-01058-2.

[27] V. Giroux and A. K. Rustgi, “Metaplasia: Tissue Injury Adaptation and a Precursor to the Dysplasia-Cancer Sequence,” Nature Reviews Cancer 17 (2017): 594–604.

[28] R. F. Souza and S. J. Spechler, “Mechanisms and Pathophysiology of Barrett Oesophagus,” Nature reviews Gastroenterology & Hepatology 19 (2022): 605–620.

[29] P. Storz, “Acinar Cell Plasticity and Development of Pancreatic Ductal Adenocarcinoma,” Nature reviews Gastroenterology & Hepatology 14 (2017): 296–304.

[30] A. A. Connor and S. Gallinger, “Pancreatic Cancer Evolution and Heterogeneity: Integrating Omics and Clinical data,” Nature Reviews Cancer 22 (2022): 131–142.

[31] S. Hong, C. M. Heaphy, C. Shi, et al., “Telomeres Are Shortened in Acinar-to-Ductal Metaplasia Lesions Associated With Pancreatic Intraepithelial Neoplasia but not in Isolated Acinar-to-Ductal Metaplasias,” Modern Pathology 24 (2011): 256–266.

[32] J. R. Goldenring and J. C. Mills, “Cellular Plasticity, Reprogramming, and Regeneration: Metaplasia in the Stomach and Beyond,” Gastroenterology 162 (2022): 415–430.

[33] K. A. Bockerstett, S. A. Lewis, K. J. Wolf, et al., “Single-Cell Transcriptional Analyses of Spasmolytic Polypeptide-Expressing Metaplasia Arising From Acute Drug Injury and Chronic Inflammation in the Stomach,” Gut 69 (2020): 1027–1038.

[34] W. J. Huh, S. S. Khurana, J. H. Geahlen, K. Kohli, R. A. Waller, and J. C. Mills, “Tamoxifen Induces Rapid, Reversible Atrophy, and Metaplasia in Mouse Stomach,” Gastroenterology 142 (2012): 21–24. e27.

[35] K. T. Nam, H. Lee, J. F. Sousa, et al., “Mature Chief Cells Are Cryptic Progenitors for Metaplasia in the Stomach,” Gastroenterology 139 (2010): 2028–2037.e2029.

[36] S. G. Willet, M. A. Lewis, Z. Miao, et al., “Regenerative Proliferation of Differentiated Cells by mTORC1-Dependent Paligenosis,” EMBO Journal 37 (2018): e98311,

[37] E. Choi, A. M. Hendley, J. M. Bailey, S. D. Leach, and J. R. Goldenring, “Expression of Activated Ras in Gastric Chief Cells of Mice Leads to the Full Spectrum of Metaplastic Lineage Transitions,” Gastroenterology 150 (2016): 918–930. e913.

[38] J. C. Mills and J. R. Goldenring, “Metaplasia in the Stomach Arises From Gastric Chief Cells,” Cellular and Molecular Gastroenterology and Hepatology 4 (2017): 85–88.

[39] Y. Hayakawa, J. G. Fox, and T. C. Wang, “Isthmus Stem Cells Are the Origins of Metaplasia in the Gastric Corpus,” Cellular and Molecular Gastroenterology and Hepatology 4 (2017): 89–94.

[40] J. Que, K. S. Garman, R. F. Souza, and S. J. Spechler, “Pathogenesis and Cells of Origin of Barrett's Esophagus,” Gastroenterology 157 (2019): 349–364. e341.

[41] P. P. Centeno, V. Pavet, and R. Marais, “The Journey From Melanocytes to Melanoma,” Nature Reviews Cancer 23 (2023): 372–390.

[42] C. Köhler, D. Nittner, F. Rambow, et al., “Mouse Cutaneous Melanoma Induced by Mutant BRaf Arises From Expansion and Dedifferentiation of Mature Pigmented Melanocytes,” Cell Stem Cell 21 (2017): 679–693. e676.

[43] A. H. Shain and B. C. Bastian, “From Melanocytes to Melanomas,” Nature Reviews Cancer 16 (2016): 345–358.

[44] C. K. Kaufman, C. Mosimann, Z. P. Fan, et al., “A Zebrafish Melanoma Model Reveals Emergence of Neural Crest Identity During Melanoma Initiation,” Science (New York, NY) 351 (2016): aad2197.

[45] A. Baggiolini, S. J. Callahan, E. Montal, et al., “Developmental Chromatin Programs Determine Oncogenic Competence in Melanoma,” Science (New York, NY) 373 (2021): eabc1048.

[46] M. Seehawer, F. Heinzmann, L. D'Artista, et al., “Necroptosis Microenvironment Directs Lineage Commitment in Liver Cancer,” Nature 562 (2018): 69–75.

[47] A. J. Craig, J. von Felden, T. Garcia-Lezana, S. Sarcognato, and A. Villanueva, “Tumour Evolution in Hepatocellular Carcinoma,” Nature Reviews Gastroenterology & Hepatology 17 (2020): 139–152.

[48] B. Fan, Y. Malato, D. F. Calvisi, et al., “Cholangiocarcinomas Can Originate From Hepatocytes in Mice,” Journal of Clinical Investigation 122 (2012): 2911–2915.

[49] D. Tschaharganeh, W. Xue, D. Calvisi, et al., “p53-Dependent Nestin Regulation Links Tumor Suppression to Cellular Plasticity in Liver Cancer,” Cell 158 (2014): 579–592.

[50] Y. Liu, S. Zhuo, Y. Zhou, et al., “Yap-Sox9 Signaling Determines Hepatocyte Plasticity and Lineage-Specific Hepatocarcinogenesis,” Journal of Hepatology 76 (2022): 652–664.

[51] L. D'Artista, A. A. Moschopoulou, I. Barozzi, et al., “MYC Determines Lineage Commitment in KRAS-Driven Primary Liver Cancer Development,” Journal of Hepatology 79 (2023): 141–149.

[52] S. Boumahdi and F. J. de Sauvage, “The Great Escape: Tumour Cell Plasticity in Resistance to Targeted Therapy,” Nature Reviews Drug Discovery 19 (2020): 39–56.

[53] Á. Quintanal-Villalonga, J. M. Chan, H. A. Yu, et al., “Lineage Plasticity in Cancer: A Shared Pathway of Therapeutic Resistance,” Nature Reviews Clinical Oncology 17 (2020): 360–371.

[54] S. Y. Ku, S. Rosario, Y. Wang, et al., “Rb1 and Trp53 Cooperate to Suppress Prostate Cancer Lineage Plasticity, Metastasis, and Antiandrogen Resistance,” Science (New York, NY) 355 (2017): 78–83.

[55] S. Gao, S. Chen, D. Han, et al., “Chromatin Binding of FOXA1 Is Promoted by LSD1-Mediated Demethylation in Prostate Cancer,” Nature Genetics 52 (2020): 1011–1017.

[56] M. Han, F. Li, Y. Zhang, et al., “FOXA2 Drives Lineage Plasticity and KIT Pathway Activation in Neuroendocrine Prostate Cancer,” Cancer Cell 40 (2022): 1306–1323. e1308.

[57] C. Chen, W. Tran, K. Song, et al., “Temporal Evolution Reveals Bifurcated Lineages in Aggressive Neuroendocrine Small Cell Prostate Cancer Trans-Differentiation,” Cancer Cell 41 (2023): 2066–2082. e2069.

[58] Y. Xu, Y. Yang, Z. Wang, et al., “ZNF397 Deficiency Triggers TET2-Driven Lineage Plasticity and AR-Targeted Therapy Resistance in Prostate Cancer,” Cancer Discovery 14 (2024): 1496–1521.

[59] J. Guo, N. Li, Q. Liu, et al., “KMT2C Deficiency Drives Transdifferentiation of Double-Negative Prostate Cancer and Confer Resistance to AR-Targeted Therapy,” Cancer Cell 43 (2025): 1261–1278.e1210.

[60] J. M. Chan, S. Zaidi, J. R. Love, et al., “Lineage plasticity in Prostate Cancer Depends on JAK/STAT Inflammatory Signaling,” Science (New York, NY) 377 (2022): 1180–1191.

[61] A. J. Cooper, L. V. Sequist, and J. J. Lin, “Third-Generation EGFR and ALK Inhibitors: Mechanisms of Resistance and Management,” Nature Reviews Clinical Oncology 19 (2022): 499–514.

[62] J. J. Lin, A. Langenbucher, P. Gupta, et al., “Small Cell Transformation of ROS1 Fusion-Positive Lung Cancer Resistant to ROS1 Inhibition,” NPJ Precision Oncology 4 (2020): 21.

[63] N. Marcoux, S. N. Gettinger, G. O'Kane, et al., “EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes,” Journal of Clinical Oncology 37 (2019): 278–285.

[64] A. Shiba-Ishii, T. W. Johnson, I. Dagogo-Jack, et al., “Analysis of Lorlatinib Analogs Reveals a Roadmap for Targeting Diverse Compound Resistance Mutations in ALK-Positive Lung Cancer,” Nature Cancer 3 (2022): 710–722.

[65] M. Offin, J. M. Chan, M. Tenet, et al., “Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at Risk for Histologic Transformation and Inferior Clinical Outcomes,” Journal of Thoracic Oncology 14 (2019): 1784–1793.

[66] A. Quintanal-Villalonga, H. Taniguchi, Y. A. Zhan, et al., “Multiomic Analysis of Lung Tumors Defines Pathways Activated in Neuroendocrine Transformation,” Cancer Discovery 11 (2021): 3028–3047.

[67] J. Zhang, K. Zhao, W. Zhou, et al., “Tet Methylcytosine Dioxygenase 2 (TET2) Deficiency Elicits EGFR-TKI (Tyrosine Kinase Inhibitors) Resistance in Non-Small Cell Lung Cancer,” Signal Transduction and Targeted Therapy 9 (2024): 65.

[68] J. W. Park, J. K. Lee, K. M. Sheu, et al., “Reprogramming Normal Human Epithelial Tissues to a Common, Lethal Neuroendocrine Cancer Lineage,” Science (New York, NY) 362 (2018): 91–95.

[69] N. G. Balanis, K. M. Sheu, F. N. Esedebe, et al., “Pan-Cancer Convergence to a Small-Cell Neuroendocrine Phenotype That Shares Susceptibilities With Hematological Malignancies,” Cancer Cell 36 (2019): 17–34. e17.

[70] M. Fujii, S. Sekine, and T. Sato, “Decoding the Basis of Histological Variation in Human Cancer,” Nature Reviews Cancer 24 (2024): 141–158.

[71] L. Tran, J. F. Xiao, N. Agarwal, J. E. Duex, and D. Theodorescu, “Advances in Bladder Cancer Biology and Therapy,” Nature Reviews Cancer 21 (2021): 104–121.

[72] M. Wang, X. Chen, P. Tan, et al., “Acquired Semi-Squamatization During Chemotherapy Suggests Differentiation as a Therapeutic Strategy for Bladder Cancer,” Cancer Cell 40 (2022): 1044–1059. e1048.

[73] M. Bi, Z. Zhang, Y. Jiang, et al., “Enhancer Reprogramming Driven by High-Order Assemblies of Transcription Factors Promotes Phenotypic Plasticity and Breast Cancer Endocrine Resistance,” Nature Cell Biology 22 (2020): 701–715.

[74] L. Garcia-Martinez, A. M. Adams, H. L. Chan, et al., “Endocrine Resistance and Breast Cancer Plasticity Are Controlled by CoREST,” Nature Structural & Molecular Biology 29 (2022): 1122–1135.

[75] G. Xu, S. Chhangawala, E. Cocco, et al., “ARID1A Determines Luminal Identity and Therapeutic Response in Estrogen-Receptor-Positive Breast Cancer,” Nature Genetics 52 (2020): 198–207.

[76] M. P. Labrecque, I. M. Coleman, L. G. Brown, et al., “Molecular Profiling Stratifies Diverse Phenotypes of Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer,” Journal of Clinical Investigation 129 (2019): 4492–4505.

[77] A. J. Schoenfeld, J. M. Chan, D. Kubota, et al., “Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations as Early Resistance Mechanisms to First-Line Osimertinib in EGFR-Mutant Lung Cancer,” Clinical Cancer Research 26 (2020): 2654–2663.

[78] S. Park, J. Han, and J. M. Sun, “Histologic Transformation of ALK-Rearranged Adenocarcinoma to Squamous Cell Carcinoma After Treatment With ALK Inhibitor,” Lung Cancer (Amsterdam, Netherlands) 127 (2019): 66–68.

[79] M. M. Awad, S. Liu, I. I. Rybkin, et al., “Acquired Resistance to KRAS(G12C) Inhibition in Cancer,” New England Journal of Medicine 384 (2021): 2382–2393.

[80] S. Patil, B. Steuber, W. Kopp, et al., “EZH2 Regulates Pancreatic Cancer Subtype Identity and Tumor Progression via Transcriptional Repression of GATA6,” Cancer Research 80 (2020): 4620–4632.

[81] J. Andricovich, S. Perkail, Y. Kai, N. Casasanta, W. Peng, and A. Tzatsos, “Loss of KDM6A Activates Super-Enhancers to Induce Gender-Specific Squamous-Like Pancreatic Cancer and Confers Sensitivity to BET Inhibitors,” Cancer Cell 33 (2018): 512–526. e518.

[82] S. Benitz, A. Steep, M. M. Nasser, et al., “ROR2 Regulates Cellular Plasticity in Pancreatic Neoplasia and Adenocarcinoma,” Cancer Discovery 14 (2024): 2162–2182.

[83] J. Dilly, M. T. Hoffman, L. Abbassi, et al., “Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer,” Cancer Discovery 14, no. 11 (2024): 2135–2161, https://doi.org/10.1158/2159-8290.Cd-24-0177.

[84] A. Singhal, H. C. Styers, J. Rub, et al., “A Classical Epithelial State Drives Acute Resistance to KRAS Inhibition in Pancreas Cancer,” Cancer Discovery 14, no. 11 (2024): 2122–2134, https://doi.org/10.1158/2159-8290.Cd-24-0740.

[85] T. Shibue and R. A. Weinberg, “EMT, CSCs, and Drug Resistance: The Mechanistic Link and Clinical Implications,” Nature Reviews Clinical Oncology 14 (2017): 611–629.

[86] E. Baumgart, M. S. Cohen, B. S. Neto, et al., “Identification and Prognostic Significance of an Epithelial-Mesenchymal Transition Expression Profile in Human Bladder Tumors,” Clinical Cancer Research 13 (2007): 1685–1694.

[87] A. Soltermann, V. Tischler, S. Arbogast, et al., “Prognostic Significance of Epithelial-Mesenchymal and Mesenchymal-Epithelial Transition Protein Expression in Non-Small Cell Lung Cancer,” Clinical Cancer Research 14 (2008): 7430–7437.

[88] S. Vega, A. V. Morales, O. H. Ocaña, F. Valdés, I. Fabregat, and M. A. Nieto, “Snail Blocks the Cell Cycle and Confers Resistance to Cell Death,” Genes & Development 18 (2004): 1131–1143.

[89] N. K. Kurrey, S. P. Jalgaonkar, A. V. Joglekar, et al., “Snail and Slug Mediate Radioresistance and Chemoresistance by Antagonizing p53-Mediated Apoptosis and Acquiring a Stem-Like Phenotype in Ovarian Cancer Cells,” Stem Cells (Dayton, Ohio) 27 (2009): 2059–2068.

[90] M. Lu, S. Marsters, X. Ye, E. Luis, L. Gonzalez, and A. Ashkenazi, “E-Cadherin Couples Death Receptors to the Cytoskeleton to Regulate Apoptosis,” Molecular Cell 54 (2014): 987–998.

[91] T. Arumugam, V. Ramachandran, K. F. Fournier, et al., “Epithelial to Mesenchymal Transition Contributes to Drug Resistance in Pancreatic Cancer,” Cancer Research 69 (2009): 5820–5828.

[92] X. Chen, S. Lingala, S. Khoobyari, J. Nolta, M. A. Zern, and J. Wu, “Epithelial Mesenchymal Transition and Hedgehog Signaling Activation Are Associated With Chemoresistance and Invasion of Hepatoma Subpopulations,” Journal of Hepatology 55 (2011): 838–845.

[93] M. Saxena, M. A. Stephens, H. Pathak, and A. Rangarajan, “Transcription Factors That Mediate Epithelial-Mesenchymal Transition Lead to Multidrug Resistance by Upregulating ABC Transporters,” Cell Death & Disease 2 (2011): e179.

[94] X. Zheng, J. L. Carstens, J. Kim, et al., “Epithelial-to-Mesenchymal Transition Is Dispensable for Metastasis but Induces Chemoresistance in Pancreatic Cancer,” Nature 527 (2015): 525–530.

[95] M. Debaugnies, S. Rodríguez-Acebes, J. Blondeau, et al., “RHOJ Controls EMT-Associated Resistance to Chemotherapy,” Nature 616 (2023): 168–175.

[96] S. Qin, J. Jiang, Y. Lu, et al., “Emerging Role of Tumor Cell Plasticity in Modifying Therapeutic Response,” Signal Transduction and Targeted Therapy 5 (2020): 228.

[97] L. V. Sequist, B. A. Waltman, D. Dias-Santagata, et al., “Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors,” Science Translational Medicine 3 (2011): 75ra26.

[98] S. Thomson, E. Buck, F. Petti, et al., “Epithelial to Mesenchymal Transition Is a Determinant of Sensitivity of Non-Small-Cell Lung Carcinoma Cell Lines and Xenografts to Epidermal Growth Factor Receptor Inhibition,” Cancer Research 65 (2005): 9455–9462.

[99] J. Chung, J. K. Rho, X. Xu, et al., “Clinical and Molecular Evidences of Epithelial to Mesenchymal Transition in Acquired Resistance to EGFR-TKIs,” Lung Cancer (Amsterdam, Netherlands) 73 (2011): 176–182.

[100] K. Suda, K. Tomizawa, M. Fujii, et al., “Epithelial to Mesenchymal Transition in an Epidermal Growth Factor Receptor-Mutant Lung Cancer Cell Line With Acquired Resistance to Erlotinib,” Journal of Thoracic Oncology 6 (2011): 1152–1161.

[101] R. L. Yauch, T. Januario, D. A. Eberhard, et al., “Epithelial Versus Mesenchymal Phenotype Determines In Vitro Sensitivity and Predicts Clinical Activity of Erlotinib in Lung Cancer Patients,” Clinical Cancer Research 11 (2005): 8686–8698.

[102] Z. Zhang, J. C. Lee, L. Lin, et al., “Activation of the AXL Kinase Causes Resistance to EGFR-Targeted Therapy in Lung Cancer,” Nature Genetics 44 (2012): 852–860.

[103] J. Antony and R. Y. Huang, “AXL-Driven EMT State as a Targetable Conduit in Cancer,” Cancer Research 77 (2017): 3725–3732.

[104] G. Guo, K. Gong, S. Ali, et al., “A TNF-JNK-Axl-ERK Signaling Axis Mediates Primary Resistance to EGFR Inhibition in Glioblastoma,” Nature Neuroscience 20 (2017): 1074–1084.

[105] M. B. Nilsson, Y. Yang, S. Heeke, et al., “CD70 is a Therapeutic Target Upregulated in EMT-Associated EGFR Tyrosine Kinase Inhibitor Resistance,” Cancer Cell 41 (2023): 340–355. e346.

[106] K. Tanaka, H. A. Yu, S. Yang, et al., “Targeting Aurora B Kinase Prevents and Overcomes Resistance to EGFR Inhibitors in Lung Cancer by Enhancing BIM- and PUMA-Mediated Apoptosis,” Cancer Cell 39 (2021): 1245–1261. e1246.

[107] Y. Gu, Z. Zhang, and P. Ten Dijke, “Harnessing Epithelial-Mesenchymal Plasticity to Boost Cancer Immunotherapy,” Cellular & Molecular Immunology 20 (2023): 318–340.

[108] L. Lorenzo-Sanz, M. Lopez-Cerda, V. da Silva-Diz, et al., “Cancer Cell Plasticity Defines Response to Immunotherapy in Cutaneous Squamous Cell Carcinoma,” Nature Communications 15 (2024): 5352.

[109] J. D. Hendriksen, A. Locallo, S. Maarup, et al., “Immunotherapy Drives Mesenchymal Tumor Cell State Shift and TME Immune Response in Glioblastoma Patients,” Neuro-oncology 26 (2024): 1453–1466.

[110] I. Akalay, B. Janji, M. Hasmim, et al., “EMT Impairs Breast Carcinoma Cell Susceptibility to CTL-Mediated Lysis Through Autophagy Induction,” Autophagy 9 (2013): 1104–1106.

[111] I. Akalay, B. Janji, M. Hasmim, et al., “Epithelial-to-Mesenchymal Transition and Autophagy Induction in Breast Carcinoma Promote Escape From T-Cell-Mediated Lysis,” Cancer Research 73 (2013): 2418–2427.

[112] S. C. Tripathi, H. L. Peters, A. Taguchi, et al., “Immunoproteasome Deficiency Is a Feature of Non-Small Cell Lung Cancer With a Mesenchymal Phenotype and Is Associated With a Poor Outcome,” Proceedings of the National Academy of Sciences of the United States of America 113 (2016): E1555–E1564.

[113] A. Dongre, M. Rashidian, F. Reinhardt, et al., “Epithelial-to-Mesenchymal Transition Contributes to Immunosuppression in Breast Carcinomas,” Cancer Research 77 (2017): 3982–3989.

[114] I. Kim, M. S. Diamond, S. Yuan, et al., “Plasticity-Induced Repression of Irf6 Underlies Acquired Resistance to Cancer Immunotherapy in Pancreatic Ductal Adenocarcinoma,” Nature Communications 15 (2024): 1532.

[115] A. Dongre and R. A. Weinberg, “New Insights Into the Mechanisms of Epithelial-Mesenchymal Transition and Implications for Cancer,” Nature Reviews Molecular Cell Biology 20 (2019): 69–84.

[116] C. Kudo-Saito, H. Shirako, T. Takeuchi, and Y. Kawakami, “Cancer Metastasis Is Accelerated Through Immunosuppression During Snail-Induced EMT of Cancer Cells,” Cancer Cell 15 (2009): 195–206.

[117] D. Hsu, H. Wang, S. Tai, et al., “Acetylation of Snail Modulates the Cytokinome of Cancer Cells to Enhance the Recruitment of Macrophages,” Cancer Cell 26 (2014): 534–548.

[118] A. Dongre, M. Rashidian, E. N. Eaton, et al., “Direct and Indirect Regulators of Epithelial-Mesenchymal Transition-Mediated Immunosuppression in Breast Carcinomas,” Cancer Discovery 11 (2021): 1286–1305.

[119] S. Gerstberger, Q. Jiang, and K. Ganesh, “Metastasis,” Cell 186 (2023): 1564–1579.

[120] P. Karras, J. R. M. Black, N. McGranahan, and J. C. Marine, “Decoding the Interplay Between Genetic and Non-Genetic Drivers of Metastasis,” Nature 629 (2024): 543–554.

[121] M. A. Nieto, R. Y. Huang, R. A. Jackson, and J. P. Thiery, “EMT: 2016,” Cell 166 (2016): 21–45.

[122] R. Fontana, A. Mestre-Farrera, and J. Yang, “Update on Epithelial-Mesenchymal Plasticity in Cancer Progression,” Annual Review of Pathology 19 (2024): 133–156.

[123] J. Yang, S. A. Mani, J. L. Donaher, et al., “Twist, a Master Regulator of Morphogenesis, Plays an Essential Role in Tumor Metastasis,” Cell 117 (2004): 927–939.

[124] M. P. Stemmler, R. L. Eccles, S. Brabletz, and T. Brabletz, “Non-Redundant Functions of EMT Transcription Factors,” Nature Cell Biology 21 (2019): 102–112.

[125] M. Yang, M. Wu, S. Chiou, et al., “Direct Regulation of TWIST by HIF-1alpha Promotes Metastasis,” Nature Cell Biology 10 (2008): 295–305.

[126] S. C. Wei, L. Fattet, J. H. Tsai, et al., “Matrix Stiffness Drives Epithelial-Mesenchymal Transition and Tumour Metastasis Through a TWIST1-G3BP2 Mechanotransduction Pathway,” Nature Cell Biology 17 (2015): 678–688.

[127] C. Wei, C. Yang, S. Wang, et al., “Crosstalk Between Cancer Cells and Tumor Associated Macrophages Is Required for Mesenchymal Circulating Tumor Cell-Mediated Colorectal Cancer Metastasis,” Molecular Cancer 18 (2019): 64.

[128] L. Fattet, H. Jung, M. W. Matsumoto, et al., “Matrix Rigidity Controls Epithelial-Mesenchymal Plasticity and Tumor Metastasis via a Mechanoresponsive EPHA2/LYN Complex,” Developmental Cell 54 (2020): 302–316. e307.

[129] M. Alonso-Nocelo, L. Ruiz-Cañas, P. Sancho, et al., “Macrophages Direct Cancer Cells Through a LOXL2-Mediated Metastatic Cascade in Pancreatic Ductal Adenocarcinoma,” Gut 72 (2023): 345–359.

[130] J. Yang, P. Antin, G. Berx, et al., “Guidelines and Definitions for Research on Epithelial-Mesenchymal Transition,” Nature Reviews Molecular Cell Biology 21 (2020): 341–352.

[131] N. M. Aiello, R. Maddipati, R. J. Norgard, et al., “EMT Subtype Influences Epithelial Plasticity and Mode of Cell Migration,” Developmental Cell 45 (2018): 681–695. e684.

[132] I. Pastushenko, A. Brisebarre, A. Sifrim, et al., “Identification of the Tumour Transition States Occurring During EMT,” Nature 556 (2018): 463–468.

[133] P. Karras, I. Bordeu, J. Pozniak, et al., “A Cellular Hierarchy in Melanoma Uncouples Growth and Metastasis,” Nature 610 (2022): 190–198.

[134] I. Pastushenko, F. Mauri, Y. Song, et al., “Fat1 Deletion Promotes Hybrid EMT State, Tumour Stemness and Metastasis,” Nature 589 (2021): 448–455.

[135] J. Cui, C. Zhang, J. Lee, et al., “MLL3 Loss Drives Metastasis by Promoting a Hybrid Epithelial-Mesenchymal Transition State,” Nature Cell Biology 25 (2023): 145–158.

[136] T. Brabletz, A. Jung, S. Spaderna, F. Hlubek, and T. Kirchner, “Opinion: Migrating Cancer Stem Cells—An Integrated Concept of Malignant Tumour Progression,” Nature Reviews Cancer 5 (2005): 744–749.

[137] C. L. Chaffer, J. P. Brennan, J. L. Slavin, T. Blick, E. W. Thompson, and E. D. Williams, “Mesenchymal-to-Epithelial Transition Facilitates Bladder Cancer Metastasis: Role of Fibroblast Growth Factor Receptor-2,” Cancer Research 66 (2006): 11271–11278.

[138] Y. L. Chao, C. R. Shepard, and A. Wells, “Breast Carcinoma Cells Re-Express E-Cadherin During Mesenchymal to Epithelial Reverting Transition,” Molecular Cancer 9 (2010): 179.

[139] E. D. Williams, D. Gao, A. Redfern, and E. W. Thompson, “Controversies Around Epithelial-Mesenchymal Plasticity in Cancer Metastasis,” Nature Reviews Cancer 19 (2019): 716–732.

[140] M. Reichert, B. Bakir, L. Moreira, et al., “Regulation of Epithelial Plasticity Determines Metastatic Organotropism in Pancreatic Cancer,” Developmental Cell 45 (2018): 696–711. e698.

[141] O. H. Ocaña, R. Córcoles, A. Fabra, et al., “Metastatic Colonization Requires the Repression of the Epithelial-Mesenchymal Transition Inducer Prrx1,” Cancer Cell 22 (2012): 709–724.

[142] J. H. Tsai, J. L. Donaher, D. A. Murphy, S. Chau, and J. Yang, “Spatiotemporal Regulation of Epithelial-Mesenchymal Transition Is Essential for Squamous Cell Carcinoma Metastasis,” Cancer Cell 22 (2012): 725–736.

[143] A. C. Obenauf and J. Massagué, “Surviving at a Distance: Organ-Specific Metastasis,” Trends in Cancer 1 (2015): 76–91.

[144] M. Esposito, N. Mondal, T. M. Greco, et al., “Bone Vascular Niche E-Selectin Induces Mesenchymal-Epithelial Transition and Wnt Activation in Cancer Cells to Promote Bone Metastasis,” Nature Cell Biology 21 (2019): 627–639.

[145] C. Borrelli, M. Roberts, D. Eletto, et al., “In Vivo Interaction Screening Reveals Liver-Derived Constraints to Metastasis,” Nature 632 (2024): 411–418.

[146] E. Risson, A. R. Nobre, V. Maguer-Satta, and J. A. Aguirre-Ghiso, “The Current Paradigm and Challenges Ahead for the Dormancy of Disseminated Tumor Cells,” Nature Cancer 1 (2020): 672–680.

[147] D. A. Lawson, N. R. Bhakta, K. Kessenbrock, et al., “Single-Cell Analysis Reveals a Stem-Cell Program in Human Metastatic Breast Cancer Cells,” Nature 526 (2015): 131–135.

[148] K. L. Harper, M. S. Sosa, D. Entenberg, et al., “Mechanism of Early Dissemination and Metastasis in Her2(+) Mammary Cancer,” Nature 540 (2016): 588–592.

[149] A. R. Nobre, E. Dalla, J. Yang, et al., “ZFP281 Drives a Mesenchymal-Like Dormancy Program in Early Disseminated Breast Cancer Cells That Prevents Metastatic Outgrowth in the Lung,” Nature Cancer 3 (2022): 1165–1180.

[150] P. Aouad, Y. Zhang, F. De Martino, et al., “Epithelial-Mesenchymal Plasticity Determines Estrogen Receptor Positive Breast Cancer Dormancy and Epithelial Reconversion Drives Recurrence,” Nature Communications 13 (2022): 4975.

[151] S. Gawrzak, L. Rinaldi, S. Gregorio, et al., “MSK1 Regulates Luminal Cell Differentiation and Metastatic Dormancy in ER(+) Breast Cancer,” Nature Cell Biology 20 (2018): 211–221.

[152] J. J. Loh and S. Ma, “Hallmarks of Cancer Stemness,” Cell Stem Cell 31 (2024): 617–639.

[153] T. Reya, S. J. Morrison, M. F. Clarke, and I. L. Weissman, “Stem Cells, Cancer, and Cancer Stem Cells,” Nature 414 (2001): 105–111.

[154] S. J. A. Buczacki, H. I. Zecchini, A. M. Nicholson, et al., “Intestinal Label-Retaining Cells Are Secretory Precursors Expressing Lgr5,” Nature 495 (2013): 65–69.

[155] M. Shimokawa, Y. Ohta, S. Nishikori, et al., “Visualization and Targeting of LGR5(+) Human Colon Cancer Stem Cells,” Nature 545 (2017): 187–192.

[156] M. Castellan, A. Guarnieri, A. Fujimura, et al., “Single-Cell Analyses Reveal YAP/TAZ as Regulators of Stemness and Cell Plasticity in Glioblastoma,” Nature Cancer 2 (2021): 174–188.

[157] E. Batlle and H. Clevers, “Cancer Stem Cells Revisited,” Nature Medicine 23 (2017): 1124–1134.

[158] R. C. Gimple, K. Yang, M. E. Halbert, S. Agnihotri, and J. N. Rich, “Brain Cancer Stem Cells: Resilience Through Adaptive Plasticity and Hierarchical Heterogeneity,” Nature Reviews Cancer 22 (2022): 497–514.

[159] A. R. Sloan, D. J. Silver, S. Kint, M. Gallo, and J. D. Lathia, “Cancer Stem Cell Hypothesis 2.0 in Glioblastoma: Where Are We Now and Where Are We Going?,” Neuro-oncology 26 (2024): 785–795.

[160] R. Zhu, O. Gires, L. Zhu, et al., “TSPAN8 Promotes Cancer Cell Stemness via Activation of Sonic Hedgehog Signaling,” Nature Communications 10 (2019): 2863.

[161] C. Dravis, C. Chung, N. K. Lytle, et al., “Epigenetic and Transcriptomic Profiling of Mammary Gland Development and Tumor Models Disclose Regulators of Cell State Plasticity,” Cancer Cell 34 (2018): 466–482. e466.

[162] F. Rambow, A. Rogiers, O. Marin-Bejar, et al., “Toward Minimal Residual Disease-Directed Therapy in Melanoma,” Cell 174 (2018): 843–855. e819.

[163] F. Hua, S. Shang, Y. Yang, et al., “TRIB3 Interacts With β-Catenin and TCF4 to Increase Stem Cell Features of Colorectal Cancer Stem Cells and Tumorigenesis,” Gastroenterology 156 (2019): 708–721. e715.

[164] J. Ai, S. M. Wörmann, K. Görgülü, et al., “Bcl3 Couples Cancer Stem Cell Enrichment With Pancreatic Cancer Molecular Subtypes,” Gastroenterology 161 (2021): 318–332. e319.

[165] S. Deng, C. Wang, Y. Wang, et al., “Ectopic JAK-STAT Activation Enables the Transition to a Stem-Like and Multilineage State Conferring AR-Targeted Therapy Resistance,” Nature Cancer 3 (2022): 1071–1087.

[166] V. Plaks, N. Kong, and Z. Werb, “The Cancer Stem Cell Niche: How Essential Is the Niche in Regulating Stemness of Tumor Cells?,” Cell Stem Cell 16 (2015): 225–238.

[167] A. Dirkse, A. Golebiewska, T. Buder, et al., “Stem Cell-Associated Heterogeneity in Glioblastoma Results From Intrinsic Tumor Plasticity Shaped by the Microenvironment,” Nature Communications 10 (2019): 1787.

[168] A. S. Cazet, M. N. Hui, B. L. Elsworth, et al., “Targeting Stromal Remodeling and Cancer Stem Cell Plasticity Overcomes Chemoresistance in Triple Negative Breast Cancer,” Nature Communications 9 (2018): 2897.

[169] S. Su, J. Chen, H. Yao, et al., “CD10(+)GPR77(+) Cancer-Associated Fibroblasts Promote Cancer Formation and Chemoresistance by Sustaining Cancer Stemness,” Cell 172 (2018): 841–856. e816.

[170] Z. Ma, X. Li, Y. Mao, et al., “Interferon-Dependent SLC14A1(+) Cancer-Associated Fibroblasts Promote Cancer Stemness via WNT5A in Bladder Cancer,” Cancer Cell 40 (2022): 1550–1565. e1557.

[171] H. Lu, K. R. Clauser, W. L. Tam, et al., “A Breast Cancer Stem Cell Niche Supported by Juxtacrine Signalling From Monocytes and Macrophages,” Nature Cell Biology 16 (2014): 1105–1117.

[172] L. Beziaud, C. M. Young, A. M. Alonso, M. Norkin, A. R. Minafra, and J. Huelsken, “IFNγ-Induced Stem-Like State of Cancer Cells as a Driver of Metastatic Progression Following Immunotherapy,” Cell Stem Cell 30 (2023): 818–831. e816.

[173] Y. Yang, C. Chen, Q. Zuo, et al., “NARF Is a Hypoxia-Induced Coactivator for OCT4-Mediated Breast Cancer Stem Cell Specification,” Science Advances 8 (2022): eabo5000, https://doi.org/10.1126/sciadv.abo5000.

[174] A. Pietras, A. Katz, E. Ekström, et al., “Osteopontin-CD44 Signaling in the Glioma Perivascular Niche Enhances Cancer Stem Cell Phenotypes and Promotes Aggressive Tumor Growth,” Cell Stem Cell 14 (2014): 357–369.

[175] Y. A. Yabo, S. P. Niclou, and A. Golebiewska, “Cancer Cell Heterogeneity and Plasticity: A Paradigm Shift in Glioblastoma,” Neuro-oncology 24 (2022): 669–682.

[176] J. E. Ferrell,, “Bistability, Bifurcations, and Waddington's Epigenetic Landscape,” Current Biology: CB 22 (2012): R458–466.

[177] X. Lan, D. J. Jörg, F. M. G. Cavalli, et al., “Fate Mapping of Human Glioblastoma Reveals an Invariant Stem Cell Hierarchy,” Nature 549 (2017): 227–232.

[178] I. Tirosh, A. S. Venteicher, C. Hebert, et al., “Single-Cell RNA-seq Supports a Developmental Hierarchy in Human Oligodendroglioma,” Nature 539 (2016): 309–313.

[179] V. M. Wang, R. M. M. Ferreira, J. Almagro, et al., “CD9 Identifies Pancreatic Cancer Stem Cells and Modulates Glutamine Metabolism to Fuel Tumour Growth,” Nature Cell Biology 21 (2019): 1425–1435.

[180] F. de Sousa e Melo, A. V. Kurtova, J. M. Harnoss, et al., “A distinct role for Lgr5(+) stem cells in primary and metastatic colon cancer,” Nature 543 (2017): 676–680.

[181] C. Neftel, J. Laffy, M. G. Filbin, et al., “An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma,” Cell 178 (2019): 835–849. e821.

[182] A. C. Greenwald, N. G. Darnell, R. Hoefflin, et al., “Integrative Spatial Analysis Reveals a Multi-Layered Organization of Glioblastoma,” Cell 187 (2024): 2485–2501. e2426.

[183] D. Barkley, R. Moncada, M. Pour, et al., “Cancer Cell States Recur Across Tumor Types and Form Specific Interactions With the Tumor Microenvironment,” Nature Genetics 54 (2022): 1192–1201.

[184] A. S. Patel and I. Yanai, “A Developmental Constraint Model of Cancer Cell States and Tumor Heterogeneity,” Cell 187 (2024): 2907–2918.

[185] G. Ciriello, L. Magnani, S. J. Aitken, et al., “Cancer Evolution: A Multifaceted Affair,” Cancer Discovery (2023): Of1–of13, https://doi.org/10.1158/2159-8290.Cd-23-0530.

[186] E. R. Kastenhuber and S. W. Lowe, “Putting p53 in Context,” Cell 170 (2017): 1062–1078.

[187] S. R. Torborg, Z. Li, J. E. Chan, and T. Tammela, “Cellular and Molecular Mechanisms of Plasticity in Cancer,” Trends in Cancer 8 (2022): 735–746.

[188] A. M. Kaiser, A. Gatto, K. J. Hanson, et al., “p53 Governs an AT1 Differentiation Programme in Lung Cancer Suppression,” Nature 619 (2023): 851–859.

[189] J. De La O, L. L. Emerson, J. L. Goodman, et al., “Notch and Kras Reprogram Pancreatic Acinar Cells to Ductal Intraepithelial Neoplasia,” Proceedings of the National Academy of Sciences of the United States of America 105 (2008): 18907–18912.

[190] K. Bach, S. Pensa, M. Zarocsinceva, et al., “Time-Resolved Single-Cell Analysis of Brca1 Associated Mammary Tumourigenesis Reveals Aberrant Differentiation of Luminal Progenitors,” Nature Communications 12 (2021): 1502.

[191] L. Hu, L. Su, H. Cheng, et al., “Single-Cell RNA Sequencing Reveals the Cellular Origin and Evolution of Breast Cancer in BRCA1 Mutation Carriers,” Cancer Research 81 (2021): 2600–2611.

[192] M. A. Hill, W. B. Alexander, B. Guo, et al., “Kras and Tp53 Mutations Cause Cholangiocyte- and Hepatocyte-Derived Cholangiocarcinoma,” Cancer Research 78 (2018): 4445–4451.

[193] N. H. Juul, J. Yoon, M. C. Martinez, et al., “KRAS(G12D) Drives Lepidic Adenocarcinoma Through Stem-Cell Reprogramming,” Nature 619 (2023): 860–867.

[194] J. Kopp, G. von Figura, E. Mayes, et al., “Identification of Sox9-Dependent Acinar-to-Ductal Reprogramming as the Principal Mechanism for Initiation of Pancreatic Ductal Adenocarcinoma,” Cancer Cell 22 (2012): 737–750.

[195] S. Koren, L. Reavie, J. P. Couto, et al., “PIK3CA(H1047R) Induces Multipotency and Multi-Lineage Mammary Tumours,” Nature 525 (2015): 114–118.

[196] A. Van Keymeulen, M. Y. Lee, M. Ousset, et al., “Reactivation of Multipotency by Oncogenic PIK3CA Induces Breast Tumour Heterogeneity,” Nature 525 (2015): 119–123.

[197] L. Zhang, X. Zhu, C. Liu, et al., “PTEN Loss Expands the Histopathologic Diversity and Lineage Plasticity of Lung Cancers Initiated by Rb1/Trp53 Deletion,” Journal of Thoracic Oncology 18 (2023): 324–338.

[198] E. Fiorini, A. Malinova, D. Schreyer, et al., “MYC ecDNA Promotes Intratumour Heterogeneity and Plasticity in PDAC,” Nature 640 (2025): 811–820.

[199] J. Liang, X. Yao, P. Aouad, et al., “ERα Dysfunction Caused by ESR1 Mutations and Therapeutic Pressure Promotes Lineage Plasticity in ER(+) Breast Cancer,” Nature Cancer 6 (2025): 357–371.

[200] S. Eyunni, R. Mannan, Y. Zhang, et al., “Divergent FOXA1 Mutations Drive Prostate Tumorigenesis and Therapy-Resistant Cellular Plasticity,” Science (New York, NY) 389 (2025): eadv2367.

[201] Y. Zhang, J. L. Donaher, S. Das, et al., “Genome-Wide CRISPR Screen Identifies PRC2 and KMT2D-COMPASS as Regulators of Distinct EMT Trajectories That Contribute Differentially to Metastasis,” Nature Cell Biology 24 (2022): 554–564.

[202] E. Dardenne, H. Beltran, M. Benelli, et al., “N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer,” Cancer Cell 30 (2016): 563–577.

[203] G. Jeong, M. K. Park, H. Choi, et al., “NSD3-Induced Methylation of H3K36 Activates NOTCH Signaling to Drive Breast Tumor Initiation and Metastatic Progression,” Cancer Research 81 (2021): 77–90.

[204] N. T. Nguyen, S. Gevers, R. N. Kok, et al., “Lactate Controls Cancer Stemness and Plasticity Through Epigenetic Regulation,” Cell Metabolism 37 (2025): 903–919. e910.

[205] A. Kumaraswamy, Z. Duan, D. Flores, et al., “LSD1 Promotes Prostate Cancer Reprogramming by Repressing TP53 Signaling Independently of Its Demethylase Function,” JCI Insight 8 (2023): e167440, https://doi.org/10.1172/jci.insight.167440.

[206] C. Cai, H. He, S. Gao, et al., “Lysine-Specific Demethylase 1 Has Dual Functions as a Major Regulator of Androgen Receptor Transcriptional Activity,” Cell Reports 9 (2014): 1618–1627.

[207] J. Zhang, X. Fan, Y. Zhou, L. Chen, and H. Rao, “The PRMT5-LSD1 Axis Confers Slug Dual Transcriptional Activities and Promotes Breast Cancer Progression,” Journal of Experimental & Clinical Cancer Research: CR 41 (2022): 191.

[208] M. Kalisz, E. Bernardo, A. Beucher, et al., “HNF1A Recruits KDM6A to Activate Differentiated Acinar Cell Programs That Suppress Pancreatic Cancer,” EMBO Journal 39 (2020): e102808.

[209] L. Duplaquet, Y. Li, M. A. Booker, et al., “KDM6A Epigenetically Regulates Subtype Plasticity in Small Cell Lung Cancer,” Nature Cell Biology 25 (2023): 1346–1358.

[210] S. Yuan, R. Natesan, F. J. Sanchez-Rivera, et al., “Global Regulation of the Histone Mark H3K36me2 Underlies Epithelial Plasticity and Metastatic Progression,” Cancer Discovery 10 (2020): 854–871.

[211] R. Pathania, S. Ramachandran, S. Elangovan, et al., “DNMT1 Is Essential for Mammary and Cancer Stem Cell Maintenance and Tumorigenesis,” Nature Communications 6 (2015): 6910.

[212] H. Liu, Y. Song, H. Qiu, et al., “Downregulation of FOXO3a by DNMT1 Promotes Breast Cancer Stem Cell Properties and Tumorigenesis,” Cell Death and Differentiation 27 (2020): 966–983.

[213] S. Liu, K. Cheng, H. Zhang, et al., “Methylation Status of the Nanog Promoter Determines the Switch Between Cancer Cells and Cancer Stem Cells,” Advanced Science (Weinheim, Baden-Wurttemberg, Germany) 7 (2020): 1903035.

[214] X. Liu, C. Li, R. Zhang, et al., “The EZH2- H3K27me3-DNMT1 Complex Orchestrates Epigenetic Silencing of the wwc1 Gene, a Hippo/YAP Pathway Upstream Effector, in Breast Cancer Epithelial Cells,” Cellular Signalling 51 (2018): 243–256.

[215] Q. Wang, N. Liang, T. Yang, et al., “DNMT1-Mediated Methylation of BEX1 Regulates Stemness and Tumorigenicity in Liver Cancer,” Journal of Hepatology 75 (2021): 1142–1153.

[216] R. Lu, P. Wang, T. Parton, et al., “Epigenetic Perturbations by Arg882-Mutated DNMT3A Potentiate Aberrant Stem Cell Gene-Expression Program and Acute Leukemia Development,” Cancer Cell 30 (2016): 92–107.

[217] J. Gao, R. Liu, D. Feng, et al., “Snail/PRMT5/NuRD Complex Contributes to DNA Hypermethylation in Cervical Cancer by TET1 Inhibition,” Cell Death and Differentiation 28 (2021): 2818–2836.

[218] P. Su, Y. Hsu, R. Huang, et al., “TET1 Promotes 5hmC-Dependent Stemness, and Inhibits a 5hmC-Independent Epithelial-Mesenchymal Transition, in Cervical Precancerous Lesions,” Cancer Letters 450 (2019): 53–62.

[219] J. Wu, H. Li, M. Shi, et al., “TET1-Mediated DNA Hydroxymethylation Activates Inhibitors of the Wnt/β-Catenin Signaling Pathway to Suppress EMT in Pancreatic Tumor Cells,” Journal of Experimental & Clinical Cancer Research: CR 38 (2019): 348.

[220] M. Eyres, S. Lanfredini, H. Xu, et al., “TET2 Drives 5hmc Marking of GATA6 and Epigenetically Defines Pancreatic Ductal Adenocarcinoma Transcriptional Subtypes,” Gastroenterology 161 (2021): 653–668. e616.

[221] S. Eustermann, A. B. Patel, K. P. Hopfner, Y. He, and P. Korber, “Energy-Driven Genome Regulation by ATP-Dependent Chromatin Remodellers,” Nature Reviews Molecular Cell Biology 25 (2024): 309–332.

[222] P. Mittal and C. W. M. Roberts, “The SWI/SNF Complex in Cancer—Biology, Biomarkers and Therapy,” Nature Reviews Clinical Oncology 17 (2020): 435–448.

[223] Y. Kimura, A. Fukuda, S. Ogawa, et al., “ARID1A Maintains Differentiation of Pancreatic Ductal Cells and Inhibits Development of Pancreatic Ductal Adenocarcinoma in Mice,” Gastroenterology 155 (2018): 194–209. e192.

[224] W. Wang, S. C. Friedland, B. Guo, et al., “ARID1A, a SWI/SNF Subunit, Is Critical to Acinar Cell Homeostasis and Regeneration and Is a Barrier to Transformation and Epithelial-Mesenchymal Transition in the Pancreas,” Gut 68 (2019): 1245–1258.

[225] H. Tomihara, F. Carbone, L. Perelli, et al., “Loss of ARID1A Promotes Epithelial-Mesenchymal Transition and Sensitizes Pancreatic Tumors to Proteotoxic Stress,” Cancer Research 81 (2021): 332–343.

[226] J. Cyrta, A. Augspach, M. R. De Filippo, et al., “Role of Specialized Composition of SWI/SNF Complexes in Prostate Cancer Lineage Plasticity,” Nature Communications 11 (2020): 5549.

[227] E. Redin, H. Sridhar, Y. A. Zhan, et al., “SMARCA4 Controls State Plasticity in Small Cell Lung Cancer Through Regulation of Neuroendocrine Transcription Factors and REST Splicing,” Journal of Hematology & Oncology 17 (2024): 58.

[228] C. P. Concepcion, S. Ma, L. M. LaFave, et al., “Smarca4 Inactivation Promotes Lineage-Specific Transformation and Early Metastatic Features in the Lung,” Cancer Discovery 12 (2022): 562–585.

[229] P. Cammareri, M. Raponi, Y. Hong, et al., “Loss of Colonic Fidelity Enables Multilineage Plasticity and Metastasis,” Nature 644 (2025): 547–556.

[230] A. Balsalobre and J. Drouin, “Pioneer Factors as Master Regulators of the Epigenome and Cell Fate,” Nature Reviews Molecular Cell Biology 23 (2022): 449–464.

[231] A. Huyghe, A. Trajkova, and F. Lavial, “Cellular Plasticity in Reprogramming, Rejuvenation and Tumorigenesis: A Pioneer TF Perspective,” Trends in Cell Biology 34 (2024): 255–267.

[232] K. Takayama, T. Kosaka, T. Suzuki, et al., “Subtype-Specific Collaborative Transcription Factor Networks Are Promoted by OCT4 in the Progression of Prostate Cancer,” Nature Communications 12 (2021): 3766.

[233] D. Wei, L. Wang, Y. Yan, et al., “KLF4 Is Essential for Induction of Cellular Identity Change and Acinar-to-Ductal Reprogramming During Early Pancreatic Carcinogenesis,” Cancer Cell 29 (2016): 324–338.

[234] P. R. Tata, R. D. Chow, S. V. Saladi, et al., “Developmental History Provides a Roadmap for the Emergence of Tumor Plasticity,” Developmental Cell 44 (2018): 679–693. e675.

[235] X. Lu, V. Keo, I. Cheng, et al., “NKX2-1 Drives Neuroendocrine Transdifferentiation of Prostate Cancer via Epigenetic and 3D Chromatin Remodeling,” Nature Genetics 57 (2025): 1966–1980.

[236] S. Saghafinia, K. Homicsko, A. Di Domenico, et al., “Cancer Cells Retrace a Stepwise Differentiation Program During Malignant Progression,” Cancer Discovery 11 (2021): 2638–2657.

[237] N. R. Campbell, A. Rao, M. V. Hunter, et al., “Cooperation Between Melanoma Cell States Promotes Metastasis Through Heterotypic Cluster Formation,” Developmental Cell 56 (2021): 2808–2825.e2810.

[238] S. Linder, M. Hoogstraat, S. Stelloo, et al., “Drug-Induced Epigenomic Plasticity Reprograms Circadian Rhythm Regulation to Drive Prostate Cancer Toward Androgen Independence,” Cancer Discovery 12 (2022): 2074–2097.

[239] S. C. Baca, D. Y. Takeda, J. Seo, et al., “Reprogramming of the FOXA1 Cistrome in Treatment-Emergent Neuroendocrine Prostate Cancer,” Nature Communications 12 (2021): 1979.

[240] A. Davies, S. Nouruzi, D. Ganguli, et al., “An Androgen Receptor Switch Underlies Lineage Infidelity in Treatment-Resistant Prostate Cancer,” Nature Cell Biology 23 (2021): 1023–1034.

[241] B. Lim, K. Domsch, M. Mall, and I. Lohmann, “Canalizing Cell Fate by Transcriptional Repression,” Molecular Systems Biology 20 (2024): 144–161.

[242] B. Lim, A. Kamal, B. Gomez Ramos, et al., “Active Repression of Cell Fate Plasticity by PROX1 Safeguards Hepatocyte Identity and Prevents Liver Tumorigenesis,” Nature Genetics 57 (2025): 668–679.

[243] K. E. de Visser and J. A. Joyce, “The Evolving Tumor Microenvironment: From Cancer Initiation to Metastatic Outgrowth,” Cancer Cell 41 (2023): 374–403.

[244] Y. Chhabra and A. T. Weeraratna, “Fibroblasts in Cancer: Unity in Heterogeneity,” Cell 186 (2023): 1580–1609.

[245] P. Nallasamy, R. K. Nimmakayala, S. Karmakar, et al., “Pancreatic Tumor Microenvironment Factor Promotes Cancer Stemness via SPP1-CD44 Axis,” Gastroenterology 161 (2021): 1998–2013.e1997.

[246] S. Guinn, B. Kinny-Köster, J. A. Tandurella, et al., “Transfer Learning Reveals Cancer-Associated Fibroblasts Are Associated With Epithelial-Mesenchymal Transition and Inflammation in Cancer Cells in Pancreatic Ductal Adenocarcinoma,” Cancer Research 84 (2024): 1517–1533.

[247] S. Parte, A. B. Kaur, R. K. Nimmakayala, et al., “Cancer-Associated Fibroblast Induces Acinar-to-Ductal Cell Transdifferentiation and Pancreatic Cancer Initiation via LAMA5/ITGA4 Axis,” Gastroenterology 166 (2024): 842–858. e845.

[248] W. Chen, C. Ho, Y. Chang, et al., “Cancer-Associated Fibroblasts Regulate the Plasticity of Lung Cancer Stemness via Paracrine Signalling,” Nature Communications 5 (2014): 3472.

[249] L. Sun, Y. Wang, L. Wang, et al., “Resolvin D1 Prevents Epithelial-Mesenchymal Transition and Reduces the Stemness Features of Hepatocellular Carcinoma by Inhibiting Paracrine of Cancer-Associated Fibroblast-Derived COMP,” Journal of Experimental & Clinical Cancer Research: CR 38 (2019): 170.

[250] J. L. Hu, W. Wang, X. L. Lan, et al., “CAFs Secreted Exosomes Promote Metastasis and Chemotherapy Resistance by Enhancing Cell Stemness and Epithelial-Mesenchymal Transition in Colorectal Cancer,” Molecular Cancer 18 (2019): 91.

[251] Y. Lin, Q. Cai, Y. Chen, et al., “CAFs Shape Myeloid-Derived Suppressor Cells to Promote Stemness of Intrahepatic Cholangiocarcinoma Through 5-Lipoxygenase,” Hepatology (Baltimore, Md) 75 (2022): 28–42.

[252] D. Bayik and J. D. Lathia, “Cancer Stem Cell-Immune Cell Crosstalk in Tumour Progression,” Nature Reviews Cancer 21 (2021): 526–536.

[253] T. Hara, R. Chanoch-Myers, N. D. Mathewson, et al., “Interactions Between Cancer Cells and Immune Cells Drive Transitions to Mesenchymal-Like States in Glioblastoma,” Cancer Cell 39 (2021): 779–792. e711.

[254] K. Bhat, V. Balasubramaniyan, B. Vaillant, et al., “Mesenchymal Differentiation Mediated by NF-κB Promotes Radiation Resistance in Glioblastoma,” Cancer Cell 24 (2013): 331–346.

[255] M. Casanova-Acebes, E. Dalla, A. M. Leader, et al., “Tissue-Resident Macrophages Provide a Pro-Tumorigenic Niche to Early NSCLC Cells,” Nature 595 (2021): 578–584.

[256] R. Li, J. R. Ferdinand, K. W. Loudon, et al., “Mapping Single-Cell Transcriptomes in the Intra-Tumoral and Associated Territories of Kidney Cancer,” Cancer Cell 40 (2022): 1583–1599. e1510.

[257] P. Peng, H. Zhu, D. Liu, et al., “TGFBI Secreted by Tumor-Associated Macrophages Promotes Glioblastoma Stem Cell-Driven Tumor Growth via Integrin αvβ5-Src-Stat3 Signaling,” Theranostics 12 (2022): 4221–4236.

[258] V. P. Sharma, B. Tang, Y. Wang, et al., “Live Tumor Imaging Shows Macrophage Induction and TMEM-Mediated Enrichment of Cancer Stem Cells During Metastatic Dissemination,” Nature Communications 12 (2021): 7300.

[259] J. M. Chan, Á. Quintanal-Villalonga, V. R. Gao, et al., “Signatures of Plasticity, Metastasis, and Immunosuppression in an Atlas of Human Small Cell Lung Cancer,” Cancer Cell 39 (2021): 1479–1496. e1418.

[260] M. Tu, L. Klein, E. Espinet, et al., “TNF-α-Producing Macrophages Determine Subtype Identity and Prognosis via AP1 Enhancer Reprogramming in Pancreatic Cancer,” Nature Cancer 2 (2021): 1185–1203.

[261] T. Cui, I. Kryczek, L. Zhao, et al., “Myeloid-Derived Suppressor Cells Enhance Stemness of Cancer Cells by Inducing MicroRNA101 and Suppressing the Corepressor CtBP2,” Immunity 39 (2013): 611–621.

[262] R. Zhang, M. Dong, J. Tu, et al., “PMN-MDSCs Modulated by CCL20 From Cancer Cells Promoted Breast Cancer Cell Stemness Through CXCL2-CXCR2 Pathway,” Signal Transduction and Targeted Therapy 8 (2023): 97.

[263] L. Ai, S. Mu, C. Sun, et al., “Myeloid-Derived Suppressor Cells Endow Stem-Like Qualities to Multiple Myeloma Cells by Inducing piRNA-823 Expression and DNMT3B Activation,” Molecular Cancer 18 (2019): 88.

[264] S. Peyvandi, M. Bulliard, A. Yilmaz, et al., “Tumor-Educated Gr1+CD11b+ Cells Drive Breast Cancer Metastasis via OSM/IL-6/JAK-Induced Cancer Cell Plasticity,” Journal of Clinical Investigation 134 (2024): e166847, https://doi.org/10.1172/jci166847.

[265] S. Zhou, D. Yin, Z. Hu, et al., “A Positive Feedback Loop Between Cancer Stem-Like Cells and Tumor-Associated Neutrophils Controls Hepatocellular Carcinoma Progression,” Hepatology (Baltimore, Md) 70 (2019): 1214–1230.

[266] S. Camargo, O. Moskowitz, A. Giladi, et al., “Neutrophils Physically Interact With Tumor Cells to Form a Signaling Niche Promoting Breast Cancer Aggressiveness,” Nature Cancer 6 (2025): 540–558.

[267] Y. J. Kim, K. M. Sheu, J. Tsoi, et al., “Melanoma Dedifferentiation Induced by IFN-γ Epigenetic Remodeling in Response to Anti-PD-1 Therapy,” Journal of Clinical Investigation 131 (2021): e145859, https://doi.org/10.1172/jci145859.

[268] Del E. Del Poggetto, I. Ho, C. Balestrieri, et al., “Epithelial Memory of Inflammation Limits Tissue Damage While Promoting Pancreatic Tumorigenesis,” Science (New York, NY) 373 (2021): eabj0486.

[269] W. Hill, E. L. Lim, C. E. Weeden, et al., “Lung Adenocarcinoma Promotion by Air Pollutants,” Nature 616 (2023): 159–167.

[270] D. Alonso-Curbelo, Y. Ho, C. Burdziak, et al., “A Gene-Environment-Induced Epigenetic Program Initiates Tumorigenesis,” Nature 590 (2021): 642–648.

[271] M. V. Hunter, E. Joshi, S. Bowker, et al., “Mechanical Confinement Governs Phenotypic Plasticity in Melanoma,” Nature 647 (2025): 517–527, https://doi.org/10.1038/s41586-025-09445-6.

[272] Y. Yan, M. He, L. Zhao, et al., “A novel HIF-2α Targeted Inhibitor Suppresses Hypoxia-Induced Breast Cancer Stemness via SOD2-mtROS-PDI/GPR78-UPR(ER) Axis,” Cell Death and Differentiation 29 (2022): 1769–1789.

[273] X. Wei, Y. Chen, X. Jiang, et al., “Mechanisms of Vasculogenic Mimicry in Hypoxic Tumor Microenvironments,” Molecular Cancer 20 (2021): 7.

[274] T. Fu, S. Coulter, E. Yoshihara, et al., “FXR Regulates Intestinal Cancer Stem Cell Proliferation,” Cell 176 (2019): 1098–1112. e1018.

[275] F. Huang, Z. Liu, Y. Song, et al., “Bile Acids Activate Cancer-Associated Fibroblasts and Induce an Immunosuppressive Microenvironment in Cholangiocarcinoma,” Cancer Cell 43 (2025): 1460–1475. e1410.

[276] S. Yuan, K. S. Stewart, Y. Yang, et al., “Ras Drives Malignancy Through Stem Cell Crosstalk With the Microenvironment,” Nature 612 (2022): 555–563.

[277] E. Langille, K. N. Al-Zahrani, Z. Ma, et al., “Loss of Epigenetic Regulation Disrupts Lineage Integrity, Induces Aberrant Alveogenesis, and Promotes Breast Cancer,” Cancer Discovery 12 (2022): 2930–2953.

[278] E. M. Schaeffer, S. Srinivas, N. Adra, et al., “Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology,” Journal of the National Comprehensive Cancer Network: JNCCN 21 (2023): 1067–1096.

[279] G. J. Riely, D. E. Wood, D. L. Aisner, et al., “NCCN Guidelines® Insights: Non-Small Cell Lung Cancer, Version 7.2025,” Journal of the National Comprehensive Cancer Network: JNCCN 23 (2025): 354–362.

[280] F. C. Saalfeld, J. Möller, P. Christopoulos, et al., “Small Cell Transformation in EGFR-Mutated Non-Small Cell Lung Cancer: DLL3 Expression and Efficacy of Immune Checkpoint Inhibitors or Tyrosine Kinase Inhibitors Combined With Chemotherapy,” European Journal of Cancer (Oxford, England: 1990) 213 (2024): 115065.

[281] W. Wang and J. I. Epstein, “Small Cell Carcinoma of the Prostate. A Morphologic and Immunohistochemical Study of 95 Cases,” American Journal of Surgical Pathology 32 (2008): 65–71.

[282] N. Hitchen, A. Shahnam, and J. Tie, “Circulating Tumor DNA: A Pan-Cancer Biomarker in Solid Tumors With Prognostic and Predictive Value,” Annual Review of Medicine 76 (2025): 207–223.

[283] J. E. Berchuck, S. C. Baca, H. M. McClure, et al., “Detecting Neuroendocrine Prostate Cancer Through Tissue-Informed Cell-Free DNA Methylation Analysis,” Clinical Cancer Research 28 (2022): 928–938.

[284] H. Beltran, A. Romanel, V. Conteduca, et al., “Circulating Tumor DNA Profile Recognizes Transformation to Castration-Resistant Neuroendocrine Prostate Cancer,” Journal of Clinical Investigation 130 (2020): 1653–1668.

[285] G. M. Franceschini, O. Quaini, K. Mizuno, et al., “Noninvasive Detection of Neuroendocrine Prostate Cancer Through Targeted Cell-Free DNA Methylation,” Cancer Discovery 14 (2024): 424–445.

[286] N. De Sarkar, R. D. Patton, A. Doebley, et al., “Nucleosome Patterns in Circulating Tumor DNA Reveal Transcriptional Regulation of Advanced Prostate Cancer Phenotypes,” Cancer Discovery 13 (2023): 632–653.

[287] M. N. Sharifi, J. M. Sperger, A. K. Taylor, et al., “High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes,” Cancer Discovery 15 (2025): 969–987.

[288] S. Tendler, M. P. Dunphy, M. Agee, et al., “Imaging With [(89)Zr]Zr-DFO-SC16.56 Anti-DLL3 Antibody in Patients With High-Grade Neuroendocrine Tumours of the Lung and Prostate: A Phase 1/2, First-in-Human Trial,” Lancet Oncology 25 (2024): 1015–1024.

[289] M. F. Chen, S. Rakhade, A. Quintanal-Villalonga, et al., “Osimertinib, Platinum, Etoposide as Initial Treatment for Patients With EGFR Mutant Lung Cancers With TP53 and RB1 Alterations,” Journal of Clinical Oncology 42 (2024): 8565–8565.

[290] A. Quintanal-Villalonga, K. Kawasaki, E. Redin, et al., “CDC7 Inhibition Impairs Neuroendocrine Transformation in Lung and Prostate Tumors Through MYC Degradation,” Signal Transduction and Targeted Therapy 9 (2024): 189.

[291] J. Lengrand, I. Pastushenko, S. Vanuytven, et al., “Pharmacological Targeting of Netrin-1 Inhibits EMT in Cancer,” Nature 620 (2023): 402–408.

[292] P. A. Cassier, R. Navaridas, M. Bellina, et al., “Netrin-1 Blockade Inhibits Tumour Growth and EMT Features in Endometrial Cancer,” Nature 620 (2023): 409–416.

[293] Y. Dong, H. Hu, X. Zhang, et al., “Phosphorylation of PHF2 by AMPK Releases the Repressive H3K9me2 and Inhibits Cancer Metastasis,” Signal Transduction and Targeted Therapy 8 (2023): 95.

[294] D. Tong, Q. Liu, G. Liu, et al., “Metformin Inhibits Castration-Induced EMT in Prostate Cancer by Repressing COX2/PGE2/STAT3 Axis,” Cancer Letters 389 (2017): 23–32.

[295] A. You, M. Cao, Z. Guo, et al., “Metformin Sensitizes Sorafenib to Inhibit Postoperative Recurrence and Metastasis of Hepatocellular Carcinoma in Orthotopic Mouse Models,” Journal of Hematology & Oncology 9 (2016): 20.

[296] P. J. Goodwin, B. E. Chen, K. A. Gelmon, et al., “Effect of Metformin Versus Placebo on New Primary Cancers in Canadian Cancer Trials Group MA.32: A Secondary Analysis of a Phase III Randomized Double-Blind Trial in Early Breast Cancer,” Journal of Clinical Oncology 41 (2023): 5356–5362.

[297] P. J. Goodwin, B. E. Chen, K. A. Gelmon, et al., “Effect of Metformin Vs Placebo on Invasive Disease-Free Survival in Patients With Breast Cancer: The MA.32 Randomized Clinical Trial,” JAMA 327 (2022): 1963–1973.

[298] O. H. Y. Yu and S. Suissa, “Metformin and Cancer: Solutions to a Real-World Evidence Failure,” Diabetes Care 46 (2023): 904–912.

[299] V. Ramesh, T. Brabletz, and P. Ceppi, “Targeting EMT in Cancer With Repurposed Metabolic Inhibitors,” Trends in Cancer 6 (2020): 942–950.

[300] N. Zhang, A. S. Ng, S. Cai, Q. Li, L. Yang, and D. Kerr, “Novel Therapeutic Strategies: Targeting Epithelial-Mesenchymal Transition in Colorectal Cancer,” Lancet Oncology 22 (2021): e358–e368.

[301] J. K. Lee, J. W. Phillips, B. A. Smith, et al., “N-Myc Drives Neuroendocrine Prostate Cancer Initiated From Human Prostate Epithelial Cells,” Cancer Cell 29 (2016): 536–547.

[302] X. Gong, J. Du, S. H. Parsons, et al., “Aurora A Kinase Inhibition Is Synthetic Lethal With Loss of the RB1 Tumor Suppressor Gene,” Cancer Discovery 9 (2019): 248–263.

[303] H. Beltran, C. Oromendia, D. C. Danila, et al., “A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients With Castration-Resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers,” Clinical Cancer Research 25 (2019): 43–51.

[304] X. Le, Y. Elamin, M. Altan, et al., “16P A Phase Ib/II Trial to Evaluate Safety and Efficacy of Aurora Kinase Inhibitor LY3295668 in Combination With Osimertinib for Patients With EGFR-Mutant Non-Small Cell Lung Cancer,” ESMO Open 9 (2024), https://doi.org/10.1016/j.esmoop.2024.102595.

[305] S. Chakraborty, C. Coleman, P. Manoj, et al., “De Novo and Histologically Transformed Small-Cell Lung Cancer Is Sensitive to Lurbinectedin Treatment Through the Modulation of EMT and NOTCH Signaling Pathways,” Clinical Cancer Research 29 (2023): 3526–3540.

[306] V. Gambardella, J. C. Castillon, Y. Kuboki, et al., “725MO Phase I Trial of the DLL3/CD3 IgG-Like T Cell Engager BI 764532 in Patients (Pts) With DLL3-Positive (+) Tumours: Focus on Neuroendocrine Carcinomas,” Annals of Oncology 34 (2023): S499–S500.

[307] M. J. Giffin, K. Cooke, E. K. Lobenhofer, et al., “AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer,” Clinical Cancer Research 27 (2021): 1526–1537.

[308] R. Aggarwal, S. Rottey, A. Bernard-Tessier, et al., “Safety and Efficacy of Tarlatamab in Patients With Neuroendocrine Prostate Cancer: Results From the Phase 1b DeLLpro-300 Study,” Clinical Cancer Research 31, no. 18 (2025): 3854–3863, https://doi.org/10.1158/1078-0432.Ccr-25-1211.

[309] H. Beltran, M. L. Johnson, P. Jain, et al., “Updated Results From a Phase 1/2 Study of HPN328, a Tri-Specific, Half-Life (T1/2) Extended DLL3-Targeting T-Cell Engager in Patients (Pts) With Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Cancers (NEC),” Journal of Clinical Oncology 42 (2024): 8090–8090.

[310] M. Huang, Y. Ye, S. Chen, et al., “Use of All-Trans Retinoic Acid in the Treatment of Acute Promyelocytic Leukemia,” Blood 72 (1988): 567–572.

[311] U. Platzbecker, L. Adès, P. Montesinos, et al., “Arsenic Trioxide and All-Trans Retinoic Acid Combination Therapy for the Treatment of High-Risk Acute Promyelocytic Leukemia: Results From the APOLLO Trial,” Journal of Clinical Oncology 43, no. 29 (2025): 3160–3169, https://doi.org/10.1200/jco-25-00535.

[312] H. de Thé, “Differentiation Therapy Revisited,” Nature Reviews Cancer 18 (2018): 117–127.

[313] A. Hosseini, A. Dhall, N. Ikonen, et al., “Perturbing LSD1 and WNT Rewires Transcription to Synergistically Induce AML Differentiation,” Nature 642 (2025): 508–518.

[314] M. Bagheri, G. A. Mohamed, M. A. Mohamed Saleem, et al., “Pharmacological Induction of Chromatin Remodeling Drives Chemosensitization in Triple-Negative Breast Cancer,” Cell Reports Medicine 5 (2024): 101504.

[315] T. Pascual, M. Oliveira, P. Villagrasa, et al., “Neoadjuvant Eribulin in HER2-Negative Early-Stage Breast Cancer (SOLTI-1007-NeoEribulin): A Multicenter, Two-Cohort, Non-Randomized Phase II Trial,” NPJ Breast Cancer 7 (2021): 145.

[316] C. Yin, Y. Lin, X. Zhang, et al., “Differentiation Therapy of Hepatocellular Carcinoma in Mice With Recombinant Adenovirus Carrying Hepatocyte Nuclear Factor-4Alpha Gene,” Hepatology (Baltimore, Md) 48 (2008): 1528–1539.

[317] C. Yin, W. Xu, W. Dong, et al., “Differentiation Therapy With Hepatocyte Nuclear Factor 4α for Patients With Hepatocellular Carcinoma,” Cell Research 35 (2025): 687–690.

[318] V. B. Venkadakrishnan, A. G. Presser, R. Singh, et al., “Lineage-Specific Canonical and Non-Canonical Activity of EZH2 in Advanced Prostate Cancer Subtypes,” Nature Communications 15 (2024): 6779.

[319] A. E. Schade, N. Perurena, Y. Yang, et al., “AKT and EZH2 Inhibitors Kill TNBCs by Hijacking Mechanisms of Involution,” Nature 635 (2024): 755–763.

[320] D. Ishay-Ronen, M. Diepenbruck, R. K. R. Kalathur, et al., “Gain Fat-Lose Metastasis: Converting Invasive Breast Cancer Cells Into Adipocytes Inhibits Cancer Metastasis,” Cancer Cell 35 (2019): 17–32. e16.

[321] L. Liu, A. Chen, Y. Li, J. Mulder, H. Heyn, and X. Xu, “Spatiotemporal Omics for Biology and Medicine,” Cell 187 (2024): 4488–4519.

[322] D. E. Wagner and A. M. Klein, “Lineage Tracing Meets Single-Cell Omics: Opportunities and Challenges,” Nature Reviews Genetics 21 (2020): 410–427.

[323] A. S. Ireland, A. M. Micinski, D. W. Kastner, et al., “MYC Drives Temporal Evolution of Small Cell Lung Cancer Subtypes by Reprogramming Neuroendocrine Fate,” Cancer Cell 38 (2020): 60–78. e12.

[324] M. Zou, R. Toivanen, A. Mitrofanova, et al., “Transdifferentiation as a Mechanism of Treatment Resistance in a Mouse Model of Castration-Resistant Prostate Cancer,” Cancer Discovery 7 (2017): 736–749.

[325] Y. Li, Z. Lv, S. Zhang, et al., “Genetic Fate Mapping of Transient Cell Fate Reveals N-Cadherin Activity and Function in Tumor Metastasis,” Developmental Cell 54 (2020): 593–607. e595.

[326] F. Lüönd, N. Sugiyama, R. Bill, et al., “Distinct Contributions of Partial and Full EMT to Breast Cancer Malignancy,” Developmental Cell 56 (2021): 3203–3221. e3211.

[327] B. A. Biddy, W. Kong, K. Kamimoto, et al., “Single-Cell Mapping of Lineage and Identity in Direct Reprogramming,” Nature 564 (2018): 219–224.

[328] K. A. Fennell, D. Vassiliadis, E. Y. N. Lam, et al., “Non-Genetic Determinants of Malignant Clonal Fitness at Single-Cell Resolution,” Nature 601 (2022): 125–131.

[329] Y. Oren, M. Tsabar, M. S. Cuoco, et al., “Cycling Cancer Persister Cells Arise From Lineages With Distinct Programs,” Nature 596 (2021): 576–582.

[330] C. Gutierrez, A. M. Al'Khafaji, E. Brenner, et al., “Multifunctional Barcoding With ClonMapper Enables High-Resolution Study of Clonal Dynamics During Tumor Evolution and Treatment,” Nature Cancer 2 (2021): 758–772.

[331] V. G. Sankaran, J. S. Weissman, and L. I. Zon, “Cellular Barcoding to Decipher Clonal Dynamics in Disease,” Science (New York, NY) 378 (2022): eabm5874.

[332] A. McKenna, G. M. Findlay, J. A. Gagnon, M. S. Horwitz, A. F. Schier, and J. Shendure, “Whole-Organism Lineage Tracing by Combinatorial and Cumulative Genome Editing,” Science (New York, NY) 353 (2016): aaf7907.

[333] S. Bowling, D. Sritharan, F. G. Osorio, et al., “An Engineered CRISPR-Cas9 Mouse Line for Simultaneous Readout of Lineage Histories and Gene Expression Profiles in Single Cells,” Cell 181 (2020): 1410–1422. e1427.

[334] J. J. Quinn, M. G. Jones, R. A. Okimoto, et al., “Single-Cell Lineages Reveal the Rates, Routes, and Drivers of Metastasis in Cancer Xenografts,” Science (New York, NY) 371 (2021): eabc1944, https://doi.org/10.1126/science.abc1944.

[335] D. Yang, M. G. Jones, S. Naranjo, et al., “Lineage Tracing Reveals the Phylodynamics, Plasticity, and Paths of Tumor Evolution,” Cell 185 (2022): 1905–1923.e1925.

[336] L. S. Ludwig, C. A. Lareau, J. C. Ulirsch, et al., “Lineage Tracing in Humans Enabled by Mitochondrial Mutations and Single-Cell Genomics,” Cell 176 (2019): 1325–1339. e1322.

[337] L. Nitsch, C. A. Lareau, and L. S. Ludwig, “Mitochondrial Genetics Through the Lens of Single-Cell Multi-Omics,” Nature Genetics 56 (2024): 1355–1365.

[338] Y. Xiao, W. Jin, L. Ju, et al., “Tracking single-cell evolution using clock-Like chromatin accessibility loci,” Nature Biotechnology 43 (2024): 784–798, https://doi.org/10.1038/s41587-024-02241-z.

[339] K. Vandereyken, A. Sifrim, B. Thienpont, and T. Voet, “Methods and Applications for Single-Cell and Spatial Multi-Omics,” Nature Reviews Genetics 24 (2023): 494–515.

[340] A. M. Braxton, A. L. Kiemen, M. P. Grahn, et al., “3D Genomic Mapping Reveals Multifocality of Human Pancreatic Precancers,” Nature 629 (2024): 679–687.

[341] M. Sans, Y. Makino, J. Min, et al., “Spatial Transcriptomics of Intraductal Papillary Mucinous Neoplasms of the Pancreas Identifies NKX6-2 as a Driver of Gastric Differentiation and Indolent Biological Potential,” Cancer Discovery 13 (2023): 1844–1861.

[342] D. K. Mitchell, B. Burgess, E. E. White, et al., “Spatial Gene-Expression Profiling Unveils Immuno-Oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression,” Clinical Cancer Research 30 (2024): 1038–1053.

[343] M. Varrone, D. Tavernari, A. Santamaria-Martínez, L. A. Walsh, and G. Ciriello, “CellCharter Reveals Spatial Cell Niches Associated With Tissue Remodeling and Cell Plasticity,” Nature Genetics 56 (2024): 74–84.

[344] G. S. Gulati, J. P. D'Silva, Y. Liu, L. Wang, and A. M. Newman, “Profiling Cell Identity and Tissue Architecture With Single-Cell and Spatial Transcriptomics,” Nature Reviews Molecular Cell Biology 26 (2025): 11–31, https://doi.org/10.1038/s41580-024-00768-2.

[345] C. Trapnell, “Revealing gene Function With Statistical Inference at Single-Cell Resolution,” Nature Reviews Genetics 25 (2024): 623–638.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.